GB Sciences' Drug Development program endeavors to provide novel cannabinoid therapies to patients with critically unmet needs. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX™ technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program.
Mission
GB Sciences merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
Chief Science Officer
Andrea Small – Howard. PhD, MBA
Chief Science Officer
Biography
Dr. Andrea Small-Howard leverages broad bio-pharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GrowBlox Sciences, Inc.

She brings to GrowBlox Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline based on the companies’ proprietary technology suite, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All­University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

In 2011, Dr. Small-Howard founded International Biotechnology Solutions to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she has successfully completed projects within the areas of business development, corporate alliance building, product commercialization, corporate restructuring, and management of successful fundraising campaigns.

Currently, she also serves on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.
Craig Ellins
Chief Executive Officer & Director
Biography
Craig Ellins is known as an innovative entrepreneur who has consistently and accurately identified emerging market trends and created companies with proprietary products to capitalize on these trends.

After beginning his career in the import/export industry, Mr. Ellins has gone on to create innovative companies in areas ranging from technology and media to hydroponic food production and medical cannabis patient advocacy.
In recent years, Mr. Ellins has become a highly respected industry expert in the emerging medical cannabis market. As Chairman of Phototron Holdings, Inc. (PHOT) in 2009, Mr. Ellins created an education program to help medical cannabis patients cultivate personal medical cannabis. Mr. Ellins then developed GrowBLOX™, the cutting-edge medical-grade hydroponic growing chambers specifically designed for the cultivation of symptom-specific medicinal cannabis strains.

These chambers are the flagship growing mechanism for GB Sciences Nevada. Mr. Ellins’s unmatched care for patients has been fueled by his long-time desire to make medical cannabis available to those who need it. His own mother, Margie, became ill several years ago and was in such tremendous pain that the doctors didn’t know how to effectively help her. After turning to medical cannabis treatments and seeing the incredible results, he knew he must continue his efforts in the burgeoning medical cannabis industry.

Through years of study, patient advocacy, and research into specific strains, Mr. Ellins has helped hundreds of patients with medical cannabis cultivation education and support. Because he has seen firsthand how patients respond positively to medical cannabis treatments, he has dedicated his life to improving the lives of others through innovation in the medical cannabis industry. Mr. Ellins is also the Founder of The Newmanity Living Foundation, a nonprofit 50l(c)(3) dedicated to the cultivation and distribution of locally grown, pesticide and herbicide-free organic produce.
Cathryn Kennedy
Chief Financial Officer
Biography
Cathryn Kennedy has experience in a number of different financial roles at firms ranging from start-ups to public companies, she will be invaluable in supporting our growth as we work to bring relief to patients in communities across the country through medical marijuana.

Prior to joining GrowBlox Sciences, Ms. Kennedy served in a number of financial roles, including as CFO of eCommLink Inc. and as Director of SEC Reporting at Pinnacle Entertainment Inc. between 2005 and 2008. She was integral in establishing corporate governance policies, managing complex transaction processing, and handling M&A in these previous roles.

”I am excited to join the team at GrowBlox Sciences,” said Ms. Kennedy.  “We are just starting to scratch the surface of cannabis-based therapies potential to treat historically difficult diseases and conditions and I look forward to operating at the forefront of the industry alongside (CEO) Craig Ellins, (CSO) Andrea Small-Howard, and other members of the executive team to unlock this potential.”
Andrea Small – Howard. PhD, MBA
Chief Science Officer
Biography
Dr. Andrea Small-Howard leverages broad bio-pharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GrowBlox Sciences, Inc.

She brings to GrowBlox Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline based on the companies’ proprietary technology suite, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All­University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

In 2011, Dr. Small-Howard founded International Biotechnology Solutions to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she has successfully completed projects within the areas of business development, corporate alliance building, product commercialization, corporate restructuring, and management of successful fundraising campaigns.

Currently, she also serves on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.
Our Team
Lucas Marin
Director of Product Development
Biography
In addition to being our Director of product development Lucas Marin is also a founding member of the GrowBlox Sciences team. 

With a solid background in new product development and industrial design, Mr. Marin brings to the team a strong comprehension of managing logistics and supply chains for the bioceutical and nutraceutical markets.  

Most recently, Mr. Marin has worked on developing antibacterial topical compounds and surfactants for professional sports and private medical facilities.

In addition to his experience in development of new products Mr. Marin has spent the last decade designing experiential marketing campaigns and product launches for top-tier organizations such as Medco, AOL, SPRINT and WIRED Magazine.
Dr. Long Nguyen
Director of Technology
Biography
Dr. Long Nguyen combines a deep-rooted knowledge of scientific research with an entrepreneurial vision of technology. An underlying theme of his research has been the collection and analysis of “big data” to gain insights that would otherwise remain hidden.

Dr. Nguyen has architected and implemented software development methodologies on an enterprise scale for over a decade at Discover Financial Services, Inc. and other large financial, insurance, and retail clients. He cofounded a Y Combinator-funded startup in 2008. Focusing on the infrastructure and technology that enables an idea, projects since then have included monitoring and visualization of network-connected systems and a broadcast network for short-form video.

Dr. Nguyen received a Bachelor of Science in Physics from Harvard (Summa Cum Laude, Phi Beta Kappa) and a Doctorate in physics from the University of Chicago.
Wayne Love
Lead Product Engineer
Biography
Wayne Love brings his broad experience in engineering to GrowBlox Sciences, Inc. An experienced engineering consultant and R&D engineer, he has spent the past fifteen months living and working in China to perfect the GrowBLOX™ chamber and to assist in its scale-up for full manufacturing. He is educated, trained, and experienced in equipment engineering, robotics, computer numerical control (CNC) programming, CNC manufacturing, product design, and computer-aided design (CAD).

Mr. Love’s rich and interesting work history includes helping to bring to life the Robosaurus, a fire-breathing, car-crushing monster robot. Mr. Love studied at the University of Advancing Computer Technology in Phoenix, Arizona.
Ulrich Reimann-Philipp, PhD
Cultivation Manager
Biography
Dr. Ulrich Reimann-Philipp aims to apply his extensive academic and private-sector research experience to the transition of cannabis from pot to medicine. An expert in growing plants under laboratory conditions, Dr. Ulrich Reimann-Philipp specializes in purification and characterization of plant chemical products, plant molecular genetics, and plant defenses against pests and pathogens, in both conventionally and in hydroponic systems.

He is a noted plant biologist and water-quality expert, and he is named as the inventor of several US patents. Dr. Ulrich Reimann-Philipp received his PhD in Plant Science from the University of Kiel, Germany.
Scientific Advisory Board
Helen Turner
PhD
Biography
Dr. Helen Turner will be instrumental in developing preclinical trials of GB Sciences’ proprietary cannabinoid therapies and CME-accredited educational programs for physicians and GB Sciences’ dispensary staff members. She is Dean of Natural Sciences and Mathematics and a tenured biology Professor at Chaminade University.

She is a respected immunologist, and she holds affiliate professorship and graduate faculty appointments at the John A. Burns School of Medicine at the University of Hawaii.

Dr. Turner received her PhD in 1998 from the Imperial Cancer Research Fund, University College London, and she was a Wellcome Trust International Prize postdoctoral fellow at Beth Israel Deaconess Medical Center/Harvard Medical School from 1998 to 2000. From 2000 to 2007 she was Associate Director of Research at the Queen’s Medical Center in Hawaii, receiving her first major NIH research grant within four years of her PhD.

Dr. Turner has published several peer-reviewed research papers on cannabinoids, including CB1 and CB2 in the immune system and the ionotropic cannabinoid receptors TRPV1 and TRPA1. She is currently funded by the National Institutes of Health, the National Science Foundation, and the US Air Force. She engages in research, capacity building, and grant review for diverse state and federal agencies and is a leader in Hawaii’s statewide science capacity building efforts. She was honored as a member of the Pacific Business News 40 Under 40 class of 2009 and is a founding fellow of the academic Executive Leadership Academy at UC Berkeley. Dr. Turner is cofounder of TwoFox Concepts, LLC, a science and education consulting company.
Tony Oritz
PhD
Biography
Dr. Ortiz started his career at the University of California, Irvine Medical Center utilizing brain imaging techniques and conducting clinical trials. He has extensive experience in pre-clinical research and Pre-IND activities at Allergan, Inc., with various small and large molecules. Dr. Ortiz has consulted with various global pharmaceutical companies, such as AstraZeneca, Novo Nordisk, and Eli Lilly on their clinical

Dr. Tony Ortiz will spearhead development of human clinical trial protocols and provide regulatory guidance through the FDA process. He is the founder and Chief Executive Officer of NRC Research Institute. Dr. Ortiz has over eighteen years of experience in pharmaceutical research and development and has worked on over 250 preclinical and clinical research protocols. research programs and regulatory filings, including IND preparations and submissions.

At NRC Research Institute, Dr. Ortiz oversees the day-to-day clinical research operation, including a Phase I in-patient unit. NRC Research Institute has been involved in the FDA approval of various investigational products that are now available in the marketplace. Dr. Ortiz has served as Principal Investigator on various indications and has been awarded investigator-initiated grants from various pharmaceutical companies to investigate exploratory indications. He is trained and certified to administer various psychiatric and neuropsychological scales and assessments for the diagnosis of psychiatric/psychological disorders and diseases.
Daniel Chueh
MD
Biography
Dr. Daniel Chueh will supervise GB Sciences’ human clinical trials and formulate physician treatment protocols for GB Sciences’ cannabinoid therapies. He is the founder and Clinical Global Leader for NRC Research Institute and its worldwide operations.  The NRC Research institute is an internationally recognized, dedicated clinical research center and Contract Research Organization (CRO) for the development of investigational products.

Dr. Chueh has been the Principal Investigator for over 200 clinical trials in various indications, including but not limited to Alzheimer’s disease, bipolar disorder, Parkinson’s disease, and schizophrenia. He has been awarded investigator-initiated grants for the investigation of exploratory indications. Dr. Chueh is the Director of Psychiatry at Coastal Communities Hospital and Huntington Beach Hospital. As the Medical Director of Senior Care Communities, he has overseen the care at over twenty Alzheimer’s facilities.

More recently he has appeared on ABC’s Good Morning America as its psychiatric expert. In his spare time he produces a fishing show, Stoked on Fishing, for Fox Sports West, and he breeds and races thoroughbred horses.
Alfredo L. Axtmayer
MD
Biography
Dr. Alfredo L. Axtmayer will assist GB Sciences in its efforts to create clinical treatment protocols using cannabinoid therapies for multiple medical conditions, including pain management. He is a Clinical Instructor in Orthopaedics and Rehabilitation at Yale University School of Medicine, as well as an Assistant Clinical Professor in its Department of Orthopaedics and Rehabilitation. He is also an Associate Professor at the Mid-State Medical Center Campus Department of Surgery.

He has authored instructional course lectures on the management and diagnosis of prosthetic joint infections, hip fractures, carpal tunnel syndrome, and medial knee osteoarthritis, and he has written academy guidelines on the management of knee osteoarthritis, low back pain, hip fractures, and rotator cuff disorders. He received his BA from Yale and his MD from Yale University School of Medicine.
John Abroon
MD
Biography
Dr. John Abroon will help GB Sciences validate its cannabinoid treatment protocols. He is a board-certified general practitioner who specializes in diagnostic and preventive medicine. He completed his residency program at Westchester County Medical Center in 1986. After three years of research in liver diseases, he has published a number of articles on liver cirrhosis in The American Journal of Gastroenterology and the Journal of Hepatology.

Dr. Abroon is affiliated with Mount Sinai and Lenox Hill hospitals and has strong working relationships with prestigious New York specialists at a number of area hospitals and medical facilities. His extensive network of practitioners allows access to the latest medical information and he is able to provide patients with excellent doctor recommendations that he trusts.

In his private practice, Dr. Abroon has an interest in preventive medicine and wellness care, and he incorporates alternative therapies and good old-fashioned home remedies into cutting-edge medical practices. He ensures that each patient receives one-on-one attention, with no physician assistants or nurse practitioners seeing patients in lieu of the doctor.

He maintains affiliations with Mount Sinai and Lenox Hill hospitals in Manhattan. He received his medical degree from Universidad CIFAS. His first year of residency was completed at Cabrini Hospital in New York City and his last two years of residency were finished at Westchester County Medical Center.
GB Sciences' Drug Development program endeavors to provide novel cannabinoid therapies to patients with critically unmet needs. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX™ technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program.
Mission
GB Sciences merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
Chief Science Officer
Andrea Small – Howard. PhD, MBA
Chief Science Officer
Biography
Dr. Andrea Small-Howard leverages broad bio-pharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GrowBlox Sciences, Inc.

She brings to GrowBlox Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline based on the companies’ proprietary technology suite, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All­University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

In 2011, Dr. Small-Howard founded International Biotechnology Solutions to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she has successfully completed projects within the areas of business development, corporate alliance building, product commercialization, corporate restructuring, and management of successful fundraising campaigns.

Currently, she also serves on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.
Craig Ellins
Chief Executive Officer & Director
Biography
Craig Ellins is known as an innovative entrepreneur who has consistently and accurately identified emerging market trends and created companies with proprietary products to capitalize on these trends.

After beginning his career in the import/export industry, Mr. Ellins has gone on to create innovative companies in areas ranging from technology and media to hydroponic food production and medical cannabis patient advocacy.
In recent years, Mr. Ellins has become a highly respected industry expert in the emerging medical cannabis market. As Chairman of Phototron Holdings, Inc. (PHOT) in 2009, Mr. Ellins created an education program to help medical cannabis patients cultivate personal medical cannabis. Mr. Ellins then developed GrowBLOX™, the cutting-edge medical-grade hydroponic growing chambers specifically designed for the cultivation of symptom-specific medicinal cannabis strains.

These chambers are the flagship growing mechanism for GB Sciences Nevada. Mr. Ellins’s unmatched care for patients has been fueled by his long-time desire to make medical cannabis available to those who need it. His own mother, Margie, became ill several years ago and was in such tremendous pain that the doctors didn’t know how to effectively help her. After turning to medical cannabis treatments and seeing the incredible results, he knew he must continue his efforts in the burgeoning medical cannabis industry.

Through years of study, patient advocacy, and research into specific strains, Mr. Ellins has helped hundreds of patients with medical cannabis cultivation education and support. Because he has seen firsthand how patients respond positively to medical cannabis treatments, he has dedicated his life to improving the lives of others through innovation in the medical cannabis industry. Mr. Ellins is also the Founder of The Newmanity Living Foundation, a nonprofit 50l(c)(3) dedicated to the cultivation and distribution of locally grown, pesticide and herbicide-free organic produce.
Cathryn Kennedy
Chief Financial Officer
Biography
Cathryn Kennedy has experience in a number of different financial roles at firms ranging from start-ups to public companies, she will be invaluable in supporting our growth as we work to bring relief to patients in communities across the country through medical marijuana.

Prior to joining GrowBlox Sciences, Ms. Kennedy served in a number of financial roles, including as CFO of eCommLink Inc. and as Director of SEC Reporting at Pinnacle Entertainment Inc. between 2005 and 2008. She was integral in establishing corporate governance policies, managing complex transaction processing, and handling M&A in these previous roles.

”I am excited to join the team at GrowBlox Sciences,” said Ms. Kennedy.  “We are just starting to scratch the surface of cannabis-based therapies potential to treat historically difficult diseases and conditions and I look forward to operating at the forefront of the industry alongside (CEO) Craig Ellins, (CSO) Andrea Small-Howard, and other members of the executive team to unlock this potential.”
Andrea Small – Howard. PhD, MBA
Chief Science Officer
Biography
Dr. Andrea Small-Howard leverages broad bio-pharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GrowBlox Sciences, Inc.

She brings to GrowBlox Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline based on the companies’ proprietary technology suite, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All­University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

In 2011, Dr. Small-Howard founded International Biotechnology Solutions to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she has successfully completed projects within the areas of business development, corporate alliance building, product commercialization, corporate restructuring, and management of successful fundraising campaigns.

Currently, she also serves on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.
Scientific Advisory Board
Helen Turner
PhD
Biography
Dr. Helen Turner will be instrumental in developing preclinical trials of GB Sciences’ proprietary cannabinoid therapies and CME-accredited educational programs for physicians and GB Sciences’ dispensary staff members. She is Dean of Natural Sciences and Mathematics and a tenured biology Professor at Chaminade University.

She is a respected immunologist, and she holds affiliate professorship and graduate faculty appointments at the John A. Burns School of Medicine at the University of Hawaii.

Dr. Turner received her PhD in 1998 from the Imperial Cancer Research Fund, University College London, and she was a Wellcome Trust International Prize postdoctoral fellow at Beth Israel Deaconess Medical Center/Harvard Medical School from 1998 to 2000. From 2000 to 2007 she was Associate Director of Research at the Queen’s Medical Center in Hawaii, receiving her first major NIH research grant within four years of her PhD.

Dr. Turner has published several peer-reviewed research papers on cannabinoids, including CB1 and CB2 in the immune system and the ionotropic cannabinoid receptors TRPV1 and TRPA1. She is currently funded by the National Institutes of Health, the National Science Foundation, and the US Air Force. She engages in research, capacity building, and grant review for diverse state and federal agencies and is a leader in Hawaii’s statewide science capacity building efforts. She was honored as a member of the Pacific Business News 40 Under 40 class of 2009 and is a founding fellow of the academic Executive Leadership Academy at UC Berkeley. Dr. Turner is cofounder of TwoFox Concepts, LLC, a science and education consulting company.
Tony Oritz
PhD
Biography
Dr. Ortiz started his career at the University of California, Irvine Medical Center utilizing brain imaging techniques and conducting clinical trials. He has extensive experience in pre-clinical research and Pre-IND activities at Allergan, Inc., with various small and large molecules. Dr. Ortiz has consulted with various global pharmaceutical companies, such as AstraZeneca, Novo Nordisk, and Eli Lilly on their clinical research programs.

Dr. Tony Ortiz will spearhead development of human clinical trial protocols and provide regulatory guidance through the FDA process. He is the founder and Chief Executive Officer of NRC Research Institute. Dr. Ortiz has over eighteen years of experience in pharmaceutical research and development and has worked on over 250 preclinical and clinical research protocols. research programs and regulatory filings, including IND preparations and submissions.

At NRC Research Institute, Dr. Ortiz oversees the day-to-day clinical research operation, including a Phase I in-patient unit. NRC Research Institute has been involved in the FDA approval of various investigational products that are now available in the marketplace. Dr. Ortiz has served as Principal Investigator on various indications and has been awarded investigator-initiated grants from various pharmaceutical companies to investigate exploratory indications. He is trained and certified to administer various psychiatric and neuropsychological scales and assessments for the diagnosis of psychiatric/psychological disorders and diseases.
Daniel Chueh
MD
Biography
Dr. Daniel Chueh will supervise GB Sciences’ human clinical trials and formulate physician treatment protocols for GB Sciences’ cannabinoid therapies. He is the founder and Clinical Global Leader for NRC Research Institute and its worldwide operations.  The NRC Research institute is an internationally recognized, dedicated clinical research center and Contract Research Organization (CRO) for the development of investigational products.

Dr. Chueh has been the Principal Investigator for over 200 clinical trials in various indications, including but not limited to Alzheimer’s disease, bipolar disorder, Parkinson’s disease, and schizophrenia. He has been awarded investigator-initiated grants for the investigation of exploratory indications. Dr. Chueh is the Director of Psychiatry at Coastal Communities Hospital and Huntington Beach Hospital. As the Medical Director of Senior Care Communities, he has overseen the care at over twenty Alzheimer’s facilities.

More recently he has appeared on ABC’s Good Morning America as its psychiatric expert. In his spare time he produces a fishing show, Stoked on Fishing, for Fox Sports West, and he breeds and races thoroughbred horses.
Alfredo L. Axtmayer
MD
Biography
Dr. Alfredo L. Axtmayer will assist GB Sciences in its efforts to create clinical treatment protocols using cannabinoid therapies for multiple medical conditions, including pain management. He is a Clinical Instructor in Orthopaedics and Rehabilitation at Yale University School of Medicine, as well as an Assistant Clinical Professor in its Department of Orthopaedics and Rehabilitation. He is also an Associate Professor at the Mid-State Medical Center Campus Department of Surgery.

He has authored instructional course lectures on the management and diagnosis of prosthetic joint infections, hip fractures, carpal tunnel syndrome, and medial knee osteoarthritis, and he has written academy guidelines on the management of knee osteoarthritis, low back pain, hip fractures, and rotator cuff disorders. He received his BA from Yale and his MD from Yale University School of Medicine.
John Abroon
MD
Biography
Dr. John Abroon will help GB Sciences validate its cannabinoid treatment protocols. He is a board-certified general practitioner who specializes in diagnostic and preventive medicine. He completed his residency program at Westchester County Medical Center in 1986. After three years of research in liver diseases, he has published a number of articles on liver cirrhosis in The American Journal of Gastroenterology and the Journal of Hepatology.

Dr. Abroon is affiliated with Mount Sinai and Lenox Hill hospitals and has strong working relationships with prestigious New York specialists at a number of area hospitals and medical facilities. His extensive network of practitioners allows access to the latest medical information and he is able to provide patients with excellent doctor recommendations that he trusts.

In his private practice, Dr. Abroon has an interest in preventive medicine and wellness care, and he incorporates alternative therapies and good old-fashioned home remedies into cutting-edge medical practices. He ensures that each patient receives one-on-one attention, with no physician assistants or nurse practitioners seeing patients in lieu of the doctor.

He maintains affiliations with Mount Sinai and Lenox Hill hospitals in Manhattan. He received his medical degree from Universidad CIFAS. His first year of residency was completed at Cabrini Hospital in New York City and his last two years of residency were finished at Westchester County Medical Center.
Contact Us